Subscribe
shutterstock_547487782_fabioberti
fabioberti / Shutterstock.com
12 February 2019Asia

Pharma group asks USTR to drop India from watch list

The lobby group for India’s pharma industry has asked the  US Trade Representative (USTR) office to remove India from its Priority Watch List of places that have weak enforcement of intellectual property laws.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.


Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024

Editor's picks

Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More on this story

Big Pharma
India removes cap from patented rare disease drugs
7 January 2019   India’s Department of Pharmaceuticals has removed a price cap from a range of essential patented drugs used in the treatment of rare diseases.
Big Pharma
USTR report criticises pharma policies in Japan, NZ, Turkey
28 April 2022   US pharmaceutical and medical device industries have expressed concerns regarding the policies of several countries, according to the Office of the US Trade Representatives.

More features

Bayer gains exclusive licence for heart drug in Japan
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
McGuireWoods expands team with ex-Novo Nordisk GC
Paul, Weiss swoops for senior duo from Weil, Gotshal
UPC bans Meril Life Sciences from selling infringing heart valve
SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic
Kathi Vidal to rejoin previous firm as partner following USPTO departure
GSK triumphs in EPO appeal, revoking Pfizer patent